Drug Profile
Bosentan - Actelion
Alternative Names: Bosentan monohydrate; RO-470203; RO-470203-029; TracleerLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Actelion Pharmaceuticals; Erasmus MC
- Class Anti-inflammatories; Anti-ischaemics; Antiasthmatics; Antihypertensives; Benzene derivatives; Foot disorder therapies; Heart failure therapies; Pyrimidines; Skin disorder therapies; Small molecules; Sulfonamides; Urologics
- Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Pulmonary arterial hypertension; Skin ulcer
- Phase II Behcet's syndrome
- No development reported Diabetic foot ulcer
- Discontinued Asthma; Heart failure; Inflammatory bowel diseases; Ischaemic heart disorders; Kidney disorders; Malignant melanoma; Myocardial infarction; Pulmonary fibrosis; Reperfusion injury; Transplant rejection
Most Recent Events
- 06 Sep 2017 Actelion expects to make the 32mg dosage option of bosentan (Tracleer®) available in USA by the fourth quarter of 2017
- 06 Sep 2017 Registered for Pulmonary arterial hypertension (In children, In adolescents) (32mg) in USA (PO)
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals